A Fully Human Inhibitory Monoclonal Antibody to the Wnt Receptor RYK

Grants

Funding Acknowledgements

This work was funded partly by a Program Grant from the National Health and Medical Research Council of Australia (NHMRC) to SAS and an NHMRC Project Grant to CLP. SAS is supported by a Senior Research Fellowship from the NHMRC. CLP is supported by a Viertel Senior Medical Research Fellowship, Australia. SAS would like to acknowledge the support of the Pfizer Australia Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.